Literature DB >> 15997383

[Molecular therapy in gastroenterology and hepatology].

J Wedemeyer1, N P Malek, M P Manns, M J Bahr.   

Abstract

During recent years, molecular techniques have significantly impacted our understanding and therapeutic concepts in gastrointestinal and liver disease. In a number of diseases, diagnostic work-up includes molecular data that supplements the phenotypical evaluation. This includes monogenic diseases as well as the identification of genetic risk factors (e. g. NOD2/CARD15 mutation in Crohn's disease) and viral disease. Attempts to replace liver transplantation in hereditary liver disease by targeted molecular interventions (e. g. via viral vectors) are still experimental, but the associated techniques have improved considerably. The molecular identification of therapeutic targets was followed by the development of specifically tailored therapeutics. These agents are mainly used in the treatment of chronic inflammatory bowel disease and gastrointestinal tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15997383     DOI: 10.1007/s00108-005-1462-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  104 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

3.  Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene.

Authors:  L Mohr; S Shankara; S K Yoon; T U Krohne; M Geissler; B Roberts; H E Blum; J R Wands
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

Review 4.  Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants.

Authors:  F von Weizsäcker; S Wieland; J Köck; W B Offensperger; S Offensperger; D Moradpour; H E Blum
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

5.  Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines.

Authors:  C H Wu; G Y Wu
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

6.  Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.

Authors:  Y H Chow; B L Chiang; Y L Lee; W K Chi; W C Lin; Y T Chen; M H Tao
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

7.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

8.  Detecting colorectal cancer in stool with the use of multiple genetic targets.

Authors:  S M Dong; G Traverso; C Johnson; L Geng; R Favis; K Boynton; K Hibi; S N Goodman; M D'Allessio; P Paty; S R Hamilton; D Sidransky; F Barany; B Levin; A Shuber; K W Kinzler; B Vogelstein; J Jen
Journal:  J Natl Cancer Inst       Date:  2001-06-06       Impact factor: 13.506

Review 9.  An update on the molecular genetics of hepatocellular carcinoma.

Authors:  Arief Suriawinata; Ruliang Xu
Journal:  Semin Liver Dis       Date:  2004-02       Impact factor: 6.115

10.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.